To include your compound in the COVID-19 Resource Center, submit it here.

Lupus makes leaps with three good pieces of news

Positive data on three different mechanism provides hope in SLE

The lupus community gets its first break in a long while with three products showing efficacy in late-stage trials for systemic lupus erythematosis.

That is welcome news in a disease that saw seven compounds fail to meet primary endpoints in Phase II or Phase III trails last year, and where only one new therapy has been approved in the past 60 years (see “Target Wide, Test Narrow in Lupus”).

One of the most promising aspects is that the three therapies, for which data were

Read the full 828 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers